Scott Forrest, Ph.D.
Chief Financial Officer
Dr. Forrest is chief financial officer of Autobahn Therapeutics
Dr. Forrest brings extensive experience in corporate strategy, business development and finance to his role at Autobahn Therapeutics. Dr. Forrest joins Autobahn from Inception Therapeutics, a Versant Ventures “discovery engine” focused on building and operating transformative biotech companies, where he served as chief operating officer and chief financial officer. In this position, he played an integral leadership role in multiple companies including Lycia Therapeutics, Pipeline Therapeutics, Chinook Therapeutics and Ventus Therapeutics. Prior to Inception, Dr. Forrest was a co-founder and served as vice president of operations and corporate development at Arch-backed BlackThorn Therapeutics. Earlier, Dr. Forrest was vice president of business development at The Scripps Research Institute, overseeing the creation and launch of over 15 new biotech companies and led the negotiation and management of over $200 million in corporate alliances. He also held director or board observer positions with several companies including Zyngenia, Abide, Padlock and Epic Sciences. Dr. Forrest started his career at the University of North Carolina where he led the management of the life sciences licensing team. He also served as an entrepreneur in residence at UNC where he mentored entrepreneurs across disciplines through the “Launch the Venture” program at Kenan-Flagler Business School and was a central part of the successful launch of multiple startup companies such as Epizyme.
Dr. Forrest holds a B.S. in biochemistry from the University of Calgary and a Ph.D. in pharmacology from the University of Virginia.